Abstracts tagged "Myositis"

Abstract Number: 0712 • ACR Convergence 2021
Immune Checkpoint Inhibitor-related Myotoxicity : Musculoskeletal and/or Neuromuscular Junction Disorder ?
Hortense Chassepot¹, Lotta Plomp², Dimitri Psimaras³, Thierry Maisonobe³, Sarah Leonard Louis⁴, Isabelle Plu⁴, Mehdi Touat³, Celine Anquetil⁵, Nadege Wesner⁵, Nicolas Champtiaux⁵, Aude Rigolet⁵, Sophie Demeret³, Nicolas Weiss³, Baptiste Abbar⁶, Marie-Claire Bretagne⁷, Bruno Pinna⁷, Capucine Morelot⁸, Martin Dres⁸, Thomas Similowski⁸, Stephane Ederhy⁹, Joe-Elie Salem⁷, Olivier Benveniste⁵ and Yves Allenbach⁵, ¹Universite de Picardie Jules Verne UPJV - Amiens Picardie Hospital, Department of Clinical Immunology and Internal Medicine, Fourqueux, France, ²Amsterdam University Medical Center (AUMC), Amsterdam, Netherlands, ³Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France, ⁴Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neuropathology, Paris, France, ⁵Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, ⁶Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Oncology, Paris, France, ⁷Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, Paris, France, ⁸Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pneumology - R3S, Paris, France, ⁹Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Cardiology, Paris, France
Background/Purpose: Immune checkpoint inhibitor (ICI)-related adverse events (irAE) recently emerged as new diseases in the field of auto-immunity. Among them, ICI-related myotoxicity has the highest…
Abstract Number: 1164 • ACR Convergence 2021
A Survey of Treatment Satisfaction with Intravenous Immunoglobulin Among Patients with Inflammatory Myositis
Alan Zhou, Nancy Maltez and Catherine Ivory, University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Intravenous Immunoglobulin (IVIg) is used to treat rheumatic conditions such as Inflammatory Myositis. Subcutaneous Immunoglobulin (SCIg) is an alternative route of administering Immunoglobulin. Studies…
Abstract Number: 0690 • ACR Convergence 2021
Impact of Achieving 2016 ACR/EULAR Response Criteria on Patient Centered Outcome Measures in Myositis
Didem Saygin¹, Siamak Moghadam-Kia², Chester Oddis², Dana Ascherman², Nicole Neiman², Diane Koontz² and Rohit Aggarwal², ¹University of Chicago, Chicago, IL, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The 2016 ACR/EULAR Myositis Response Criteria represent a composite measure that is increasingly being used as a primary end point in myositis clinical trials.…
Abstract Number: 0714 • ACR Convergence 2021
Diagnostic Accuracy of Electromyogram for Myositis
Lois bolko¹, Sarah Leonard Louis², Jean hugues Salmon¹, Olivier Benveniste³, Yves Allenbach³ and Thierry Maisonobe⁴, ¹Rheumatology, CHU maison blanche, Reims, Reims, France, ²Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neuropathology, Paris, France, ³Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, ⁴Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France
Background/Purpose: The skeletal muscle biopsy is the gold standard for idiopathic inflammatory myopathies (IIM) diagnosis. Myositis specific antibodies are diagnostic biomarkers for IIM but are…
Abstract Number: 1368 • ACR Convergence 2021
Characterising Exercise Capacity in Systemic Sclerosis Using Cardiac Magnetic Resonance Imaging, Skeletal Muscle Imaging and Cardiopulmonary Exercise Testing
Laura Ross¹, Benedict Costello², Dylan Hansen³, Anniina Lindqvist², Zoe Brown⁴, Andrew Burns⁴, David Prior⁴, Wendy Stevens⁴, Marcus Pianta⁴, Warren Perera⁴, Andre La Gerche² and Mandana Nikpour¹, ¹University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ²Baker Heart and Diabetes Institute, Melbourne, Australia, ³St. Vincent’s Hospital Melbourne, Victoria, Australia, Adelaide, Australia, ⁴St Vincent's Hospital, Melbourne, Australia
Background/Purpose: Impaired exercise capacity contributes to functional impairment, negatively impacting individuals’ quality of life. Functional impairment is notable from early in the disease course of…
Abstract Number: 0691 • ACR Convergence 2021
Serum Cytokine Profiles of Patients with Adult Idiopathic Inflammatory Myopathy
Didem Saygin¹, Partha Biswas², Seyed Mehdi Nouraie², Siamak Moghadam-Kia², Mandy McGeachy², Chester Oddis², Sedin Dzanko², Diane Koontz², Dana Ascherman² and Rohit Aggarwal², ¹University of Chicago, Chicago, IL, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies are a heterogenous group of systemic autoimmune diseases characterized by muscle weakness. Serum cytokines and chemokines could shed light on disease…
Abstract Number: 0715 • ACR Convergence 2021
High-Dimensional Analysis Reveals Abnormal B Cell Subsets Associated with Specific Changes to Circulating T and Myeloid Cell Populations in Patients with Idiopathic Inflammatory Myopathies
Erin Wilfong¹, Todd Bartkowiak², Katherine Vowell¹, Camille Westlake¹, Jonathan Irish², Peggy Kendall³, Leslie Crofford¹ and Rachel Bonami¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University, Nashville, TN, ³Washington University in St. Louis, St. Louis, MO
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are a clinically heterogeneous group of conditions affecting the skin, muscle, joint, and lung in various combinations. This study…
Abstract Number: 1389 • ACR Convergence 2021
Subclinical ILD Is Frequent and Progresses Across Different Connective Tissue Diseases
Anna-Maria Hoffmann-Vold¹, Helena Andersson², Silje Reiseter², Håvard Fretheim², Imon Barua¹, Torhild Garen³, Øyvind Midtvedt¹, Ragnar Gunnarsson², Michael Durheim², Trond Mogens AAløkken² and Øyvind Molberg¹, ¹Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, Oslo University Hospital, Oslo, Nepal
Background/Purpose: Based on the argument that symptoms-define-disease, physicians commonly apply the terms pre-clinical or sub-clinical disease to describe patients with disease-related findings, but no accompanying…
Abstract Number: 0693 • ACR Convergence 2021
Discovery of Antigen Specific CD4+ T Cells in Anti-HMGCR-positive Immune Mediated Necrotizing Myopathy
Eleni Tiniakou¹, Andrew Mammen² and Erika Darrah¹, ¹Johns Hopkins University, Baltimore, MD, ²National Institutes of Health, Bethesda, MD
Background/Purpose: Anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR)-positive immune mediated necrotizing myopathy (anti-HMGCR+ IMNM) is a unique myopathy characterized by IgG autoantibodies against HMGCR and a strong…
Abstract Number: 0716 • ACR Convergence 2021
Marked Capillary Basement Membrane Reduplication Is the Hallmark Histopathological Feature of Scleromyositis
Benjamin Ellezam¹, Yves Troyanov², Valérie Leclair³, Imane Bersali⁴, Margherita Giannini⁴, Sabrina Hoa⁵, Josiane Bourré-Tessier⁵, Minoru Satoh⁶, Marvin Fritzler⁷, Béatrice Lannes⁸, Jean-Luc Senécal⁵, Marie Hudson⁹, Alain Meyer⁴ and Océane Landon-Cardinal⁵, ¹Division of Pathology, CHU Sainte-Justine; Department of Pathology and Cell Biology, Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, Hôpital du Sacré-Coeur; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ³Division of Rheumatology, Jewish General Hospital; Department of Medicine, McGill University, Montréal, QC, Canada, ⁴Service de physiologie- explorations fonctionnelles musculaire, service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg., Strasbourg, France, ⁵Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁶Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷University of Calgary, Calgary, AB, Canada, ⁸Service de Pathologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁹McGill University, Montréal, QC, Canada
Background/Purpose: Scleromyositis (SM) is an emerging subset of autoimmune myositis (AIM) in patients with features of systemic sclerosis (SSc). SM patients may present without characteristic…
Abstract Number: 1511 • ACR Convergence 2021
Investigation of Antigen Specific CD4+ T Cells in Patients with Idiopathic Inflammatory Myopathies
Begum Horuluoglu¹, Angeles Shunashy Galindo-Feria², Karine Chemin³, Genadiy Kozhukh⁴, Anatoly Dubnovitsky⁴, Vivianne Malmström⁵ and Ingrid E Lundberg⁶, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Division of Rheumatology, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden, ⁵Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Idiopathic inflammatory myopathies (IIM) also known as myositis, are rare chronic autoimmune disorders represented by lesions in muscle, skin and lung. One of the…
Abstract Number: 0694 • ACR Convergence 2021
Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Fiber Necroptosis and Muscle Inflammation and Ameliorates Muscle Weakness in Experimental Polymyositis
Mari Kamiya¹, Fumitaka Mizoguchi¹, Hirokazu Sasaki², Natsuka Umezawa¹ and Shinsuke Yasuda³, ¹Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ³Tokyo Medical and Dental University (TMDU), Tokyo, Japan
Background/Purpose: While glucocorticoids (GC) are the cornerstone of the treatment for polymyositis (PM), GC-induced myopathy is inevitable, which deteriorates muscle weakness. Therefore, novel therapeutic strategy…
Abstract Number: 0717 • ACR Convergence 2021
Association of Fatigue with Disease Activity in Myositis
Tissa Bijoy George¹, Anjana Chandrasekhara Pillai², Siamak Moghadam-Kia³, Nicole Neiman⁴, Dana Ascherman³, Chester Oddis³, Dianxu Ren⁴ and Rohit Aggarwal³, ¹UPMC McKeesport, Monroeville, PA, ²UPMC, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: The Idiopathic inflammatory myopathies are a heterogeneous group of rare systemic autoimmune diseases with muscle as the primary target. Fatigue is one of the…
Abstract Number: 1527 • ACR Convergence 2021
Effect of Rituximab on IgG Levels and Associated Infection Risk in Myositis
Michael Macklin¹, Chester Oddis², Siamak Moghadam-Kia², Dana Ascherman² and Rohit Aggarwal², ¹University of Pittsburgh, Pittsburgh, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Rituximab is an anti-CD20 antibody with therapeutic use in myositis. However, given its B cell depleting mechanism, there is concern regarding its association with…
Abstract Number: 0697 • ACR Convergence 2021
Detection of Autoantibodies Against Muscle-Specific Four-and-a-Half-LIM Domain 1 (FHL1) in Inflammatory Myopathies: Results from a Single-Center Cohort
Angeles Shunashy Galindo-Feria¹, Begum Horuluoglu¹, Jessica Day², Catia Cerqueira³, Edvard Wigren⁴, Susanne Gräslund⁴, Susanna Proudman⁵, Ingrid E Lundberg⁴ and Vidya Limaye⁶, ¹Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia and Discipline of Medicine, University of Adelaide, Adelaide, Australia, ³4Dcell, Montreuil, France, ⁴Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, ⁵University of Adelaide, Medindie, Australia, ⁶Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: Autoantibodies targeting a muscle-specific autoantigen, four-and-a-half-LIM-domain 1 (FHL1), have been previously identified in patients with idiopathic inflammatory myopathies (IIM) (1). The aim of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].